Abstract:Supplementary Tables 1-13 - PDF file 135K, Supplementary Table S1: Amplification scores and average expression scores for all paired samples based on the TCGA copy number data and gene expression data Table S2: The corr_exp_amp and corr_exp_ave for 164 genes in the 3q26-39 regions Table S3 Description of six datasets using to identify candidate driver genes Table S4 Predicted information based on GSE2109 Table S5 Predicted information based on GSE3141 Table S6 Predicted information based on GSE4573 Table S7 Predicted information based on GSE8894 Table S8 Predicted information based on GSE17710 Table S9 Predicted information based on Roepman et al. dataset Table S10 Order statistic result for 181 genes in 3q2629 Table S11 Correlation between gene expression and 3q26-29 amplification level for identified 20 genes in head and neck SCC Table S12 Correlation between gene expression and 3q26-29 amplification level for identified 20 genes in cervical SCC Table S13 Copy number alteration and mRNA expression of four genes in a panel of NSCLC cell lines (data from Cancer Cell Line Encyclopedia database)

Supplementary Table 5 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 2 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 1 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 4 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 6 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 1 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 2 from An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer

Supplementary Table 3 from An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer

Supplementary Table 1 from MAPK Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast Cancer

Supplementary Table 1 from Novel Oncogene–Induced Metastatic Prostate Cancer Cell Lines Define Human Prostate Cancer Progression Signatures

Supplementary Table 1 from CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy

Supplementary Table 1 from Genome-Wide Study of Hypomethylated and Induced Genes in Patients with Liver Cancer Unravels Novel Anticancer Targets

Supplementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from Mtor Inhibitor Therapy

Supplementary Table 3 from NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma

Supplementary Table 14 from A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance

Supplementary Tables 1-13 from Integrative Genomics Analysis Identifies Candidate Drivers at 3Q26-29 Amplicon in Squamous Cell Carcinoma of the Lung

Supplementary Table 2 from NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma